Stock Earnings

Question 1

TScan Therapeutics Inc의 주요 재무제표는 무엇인가요?

Accepted Answer

최신 재무제표(Form-10K)에 따르면, TScan Therapeutics Inc의 총 자산은 $371이며, 순loss입니다.

Question 2

TCRX의 주요 재무 비율은 무엇인가요?

Accepted Answer

TScan Therapeutics Inc의 유동비율은 2.85이고, 순이익률은 -6,350, 주당 매출은 $0.01입니다.

Question 3

TScan Therapeutics Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?

Accepted Answer

TScan Therapeutics Inc largest revenue segment is T Cell Receptor-engineered T Cell, at a revenue of 2,816,000 in the most earnings release.For geography, United States is the primary market for TScan Therapeutics Inc, at a revenue of 2,816,000.

Question 4

TScan Therapeutics Inc은 수익성이 있나요?

Accepted Answer

no, 최신 재무제표에 따르면 TScan Therapeutics Inc의 순loss은 $-127입니다.

Question 5

TScan Therapeutics Inc에 부채가 있나요?

Accepted Answer

yes, TScan Therapeutics Inc의 부채는 130입니다.

Question 6

TScan Therapeutics Inc의 발행 주식은 몇 주인가요?

Accepted Answer

TScan Therapeutics Inc의 총 발행 주식은 56.59주입니다.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	6	2	21	13	10	1
Revenue Growth (YoY)	-50%	-90%	62%	30%	900%	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	32	30	26	20	13	6
Research & Development	117	107	88	59	44	20
Operating Expenses	152	137	114	80	58	27
Other Non Operating Income (Expenses)	--	--	--	--	--	--
Pretax Income	-136	-127	-89	-66	-48	-26
Income Tax Expense	--	--	--	--	--	--
Net Income	-136	-127	-89	-66	-48	-26
Net Income Growth	31%	43%	35%	38%	85%	100%
Shares Outstanding (Diluted)	129.73	111.99	65.59	24.05	23.59	23.59
Shares Change (YoY)	14%	71%	173%	2%	0%	0%
EPS (Diluted)	-1.05	-1.13	-1.36	-2.75	-2.06	-1.11
EPS Growth	14%	-16%	-51%	34%	86%	91%
Free Cash Flow	-131	-114	-64	-70	-58	-7
Free Cash Flow Per Share	-1	-1.01	-0.97	-2.91	-2.45	-0.29
Gross Margin	--	--	--	--	--	--
Operating Margin	-2,416.66%	-6,700%	-442.85%	-507.69%	-480%	-2,600%
Profit Margin	-2,266.66%	-6,350%	-423.8%	-507.69%	-480%	-2,600%
Free Cash Flow Margin	-2,183.33%	-5,700%	-304.76%	-538.46%	-580%	-700%
EBITDA	-142	-130	-88	-61	-45	-25
EBITDA Margin	-2,366.66%	-6,500%	-419.04%	-469.23%	-450%	-2,500%
D&A For EBITDA	3	4	5	5	3	1
EBIT	-145	-134	-93	-66	-48	-26
EBIT Margin	-2,416.66%	-6,700%	-442.85%	-507.69%	-480%	-2,600%
Effective Tax Rate	--	--	--	--	--	--

TScan Therapeutics Inc (TCRX) Price

TCRX Stock Price Chart

TCRX Income

Follow-Up Questions